论文部分内容阅读
目的分析初治急性髓系白血病(AML)P-糖蛋白(P-gp)及细胞表面分化抗原的表达。方法应用流式细胞术对81例初治AML患者进行P-gp及免疫表型的检测。结果 AML中P-gp的阳性表达率为39.5%,CD34为51.9%,Ly+AML为22.2%,其中CD7阳性率最高,为12.3%。P-gp与CD34均与预后为负相关(P<0.05),Ly+AML与Ly-AML的完全缓解(CR)率无统计学差异(P>0.05)。P-gp+组中CD34的表达显著高于P-gp-组(P<0.01),其它中晚期抗原表达无统计学差异。P-gp与CD34协同表达则CR率更低(26.1%vs 82.7%)。结论 P-gp的过度表达与CD34相关,P-gp+/CD34+的AML属于一种预后不良的临床亚型。
Objective To analyze the expression of P-glycoprotein (P-gp) and cell surface differentiation antigen (AML) in newly diagnosed acute myeloid leukemia (AML). Methods Flow cytometry was used to detect the expression of P-gp and immunophenotype in 81 newly diagnosed AML patients. Results The positive expression rate of P-gp in AML was 39.5%, CD34 was 51.9%, Ly + AML was 22.2%, and the positive rate of CD7 was 12.3%. P-gp and CD34 were negatively correlated with prognosis (P <0.05). There was no significant difference in complete remission (CR) between Ly + AML and Ly-AML (P> 0.05). The expression of CD34 in P-gp + group was significantly higher than that in P-gp- group (P <0.01), and there was no significant difference in other middle and late stage antigens. The co-expression of P-gp with CD34 resulted in a lower CR rate (26.1% vs 82.7%). Conclusion The overexpression of P-gp is associated with CD34. AML with P-gp + / CD34 + is a poor prognosis clinical subtype.